Prophylaxis and treatment of cow milk fever

FIELD: stockraising.

SUBSTANCE: claimed method includes daily animal airing and feeding of propylene glycol two times per day for 10 days. Before feeding animals are aired for two hours. Before propylene glycol addition into compound feed in amount of 225-450 g per beast it is mixed with antiketosis premix containing 200 g of grass meal, 200 g of sunflower oilcake, 150 g of wheal bolting, 0.5 g of 50 % vitamin E, 500000 IU of vitamin A and 100000 IU of vitamin D, which is fed in dose of 600 g/beast per day. Mixture of propylene glycol and premix is fed on morning and evening in half daily dose with main ration, having balanced sugar/protein ratio of 1.5:1-2:1, respectively. In the first 3-4 days after ketosis detection total ration food value is decreased by 20-50 %, then during 5 days food value is gradually increased to normal one.

EFFECT: effective method for prophylaxis and treatment of cow milk fever.

2 cl, 1 tbl, 1 ex

 

The invention relates to the field of livestock and can be used in veterinary medicine, in particular in the prevention and treatment of postpartum dyspepsia (ketosis) in cows.

We know the disease is highly productive cows at the age of 5-8 years in the period of higher lactation, which is called postpartum dyspepsia animals. They have chronic indigestion feed, high concentrations in blood, urine, milk, and they exhaled air ketone (acetone) phone On the levels of these bodies in urine, milk and blood are judged on appearance of primary or secondary ketosis in animals [1].

Known complex feed additive for highly productive cows, including vitamins a, D and E, as well as salts of macro - and microelements in the following ratio, wt.%: vitamin a - 0,001-0,005; vitamin D - 0,0005-0,0010; vitamin E - 0,010-0,050; cobalt chloride - 0,002-0,004; copper sulfate - 0,020-0,040; manganese sulfate - 0,10-0,20; zinc sulfate - 0,10-0,20; fat-feed - 10-30; molasses beet 25-40 and gelatin - rest [2].

However, this feed Supplement for cows with high producing does not prevent the appearance of their postpartum dyspepsia, since it does not contain antiketogenic feed components.

The first clinical signs of ketosis is decreased appetite, this will disturb the rhythm of ruminants periods weakens peristaltic digestive tract, there is frequent evacuation of liquid feces. The amount of acetone bodies in the blood of animals is increased up to 150 mg % or more, and the amount of glucose is decreased to 25 mg %, at a rate of 62 mg %.

The task of the invention is to improve the prevention and treatment of postpartum dyspepsia in cows in the stall period content.

The essence of the invention. Method of prevention and treatment of postpartum dyspepsia in cows, including daily walks animals and feeding them propylene glycol daily for 10 days twice a day mixed with concentrates of the basic diet, and before feeding propylene glycol animals, they are subjected to a two-hour walk in the fresh air, and before the addition of propylene in the feed based 225-450 g/head per day, it is mixed with antitetanus a premix consisting of 200 g of grass meal, 200 g of sunflower meal, 150 g of wheat bran, 0.5 g 50%vitamin E, 500 thousand IU of vitamin a and 100 thousand IU of vitamin D, premix dose given 500-600 g/head / day, with a mixture of propylene glycol and premix feed in the morning and evening for half of the daily dose with the main diet, a balanced level of sugar-protein ratio in the range of 1.5:1-2,0:1, respectively. In the first 3-4 days after detection of ketosis reduce the overall nutrient density of the diet by 20-50%, after which it gradually adjusted to the Nord is s within 5 days.

Example. To determine the effectiveness of the proposed method in the stall period keeping cows was held scientific-production experience on vysokomolochnyh animals black-motley breed with signs of postpartum dyspepsia. It was formed four similar groups of experimental animals 10 animals each. The first group was the control animals did not receive propylene glycol and antipiracy premix. All animals (control and experimental groups before feeding was walking in the fresh air for 2 hours, because the movement of the animal, their muscles use acetone body as an energetic material. Animal 2, 3 and 4 groups during the first 4 days after detection of ketosis, reduced nutritional value of the diet for 40% of the derived rules, which were restored within 5 days after a decrease in acetone bodies in urine up to 10-15 mg %. In addition, within 10 days, they received propylene glycol in 220-450 g/head per day (depending on severity of disease) in a mixture of 500 g anticathode premix. Animals of group 2 was set diet with sugar-protein ratio of 1:1. Cow 3 groups during treatment received the basic diet (RR) sugar-protein ratio equal to 1.5:1, and cows 4 groups had a PR with respect to it sugar to the protein is 2:1, respectively. The level of sugar is about innovage relations in ERS balanced molasses beet, because of its digestibility for 0.5 h equal to 95%, while the grain is digested in the stomach for 13 h at 80%.

Animals had milk yield for the previous lactation on 7000-7500 kg of milk, and during the experience of their daily milk yield were within 25-26 kg of milk. In the period of experiment the basic diet for cows of the control group was basic: hay - 5,2%; haylage to 16.4%; silo - 5,7%; fodder beet - 16,8%, concentrated feed is 50.9% and beet molasses 5.0% nutrition diabetes-protein ratio of 0.8:1. Results and description of the experiment are given in table 1

Table 1
IndicatorsNormaThe group of animals
1234
Acetone bodies in urine up to experience, mg %10130135131134
Acetone bodies in 10 days experience, mg %10125803010
Blood glucose before experience, mg %50-6023212222
Glucose after 10 days of experience, mg %50-50 36455060
Sugar-protein ratio PR1:10,8:11:1the 1.5:12:1

Propylene glycol is an alcohol With3H8O2colourless opaque hygroscopic liquid without odour and taste, with a neutral reaction. Get it by chemical synthesis or by bacterial decomposition of beta-hydroxybutyric acid. Propylene glycol in the body is completely absorbed in the liver to glucose.

However, one propylene glycol, in addition to the basic ration, does not provide the required protein and carbohydrate level for vysokomolochnyh cows.

As can be seen from the table, the exercise animals outdoors ineffective (control - the first group of animals). Propylene glycol with premix gradually reduces the amount of acetone bodies in urine for 10 days of treatment up to 30 mg % and increases the level of glucose in the blood of infected animals up to 50 mg %. More effective comprehensive treatment of postpartum dyspepsia in cows when the PR that contains the level of the sugar-protein ratio in range (1,5-2):1, respectively. The number of acetone bodies in urine and blood glucose returns to normal.

Based on the results of experience, for the prevention of postpartum dispas and (ketosis), vysokoprochnym cows should be fed to the following approximate PR in winter-stall period content

FeedSugar:protein = 1,5:1Sugar:protein = 2:1
kgproteinsugarkgproteinSugar
Hay210492210492
Haylage1124222011242220
Silo10,513615613610
Beets17153850242161200
Concentrates9,56555139,5655513
Syrup0,52252821,2560675
Only-13151972-13552710

Thus, the use of predlozhenogo.potom in the prevention and treatment of postpartum dyspepsia (ketosis) in cows will effectively implement Wellness activities among vysokomolochnyh animals.

Sources of information

1. Ketosis. Clinical laboratory diagnostics. M, Agropromizdat, 1985, P.18-19.

2. USSR author's certificate No. 1419657, class. And 23 To 1/175, 1998, bull. No. 32.

1. Method of prevention and treatment of postpartum dyspepsia in cows, including daily walks animals and feeding them propylene glycol daily for 10 days twice a day mixed with concentrates of the basic diet, characterized in that before feeding propylene glycol animals subjected to a two-hour walk in the fresh air, and before the addition of propylene in the feed based 225-450 g/head per day mixed with antitetanus a premix consisting of 200 g of grass meal, 200 g of sunflower meal, 150 g of wheat bran, 0.5 g 50%vitamin E, 500 thousand IU of vitamin a and 100 thousand IU of vitamin D, premix dose given 500-600 g/head / day, with a mixture of propylene glycol and premix feed in the morning and evening for half of the daily dose with the main diet, a balanced level of sugar-protein ratio in the range of 1.5:1-2:1, respectively.

2. The method according to claim 1, characterized in that the first 3-4 days after detection of ketosis reduce the overall nutrient density of the diet by 20-50%, after which it gradually brought back to normal within 5 days.



 

Same patents:

FIELD: medicine, pharmaceutical industry.

SUBSTANCE: claimed plant tea contains tutsan (Hypericum perforatum) (grass), field horsetail (Equistetum Arvense) (grass), goosegrass (Plantaginis majoris) (leaves), Betula verricosa (grass), caseweed (Bursa pastoris) (grass), Geranium pratense (grass), Adonis vernalis (grass), Galium boreale (grass), chamomile (Matricaria recutica) (flowers), Achillea millefolium (grass), Solidago Canadensis (grass), Cichorium intibus L. (grass), dogrose (fruits), Agrimonia eupatoria (grass), Salvia officinalis (grass), Glecoma Hederacca (grass), Lunaria vulgaris (grass), and clump speedwell (Veronica longiflora) (grass) in specific ratio.

EFFECT: effective pharmaceutical agent for therapy of chronic pyelonephritis, chronic cystitis, and uroclepsia.

3 ex

FIELD: medicine.

SUBSTANCE: method involves instilling 0.5% Dioxidine solution concurrently with Enterosgel into urinary bladder in volume proportion of 1:1.

EFFECT: enhanced effectiveness of treatment; reduced toxic side action.

1 tbl

FIELD: medicine, in particular experimental biology.

SUBSTANCE: invention relates to method for prophylaxis and treatment of systemic amyloidosis and nephropathic form thereof, induced in experimental animal. In this purpose 10 % mildronate solution is hypodermically administrated to animals every second day in dose of 50 mg/kg during last 14 days of experiment.

EFFECT: effective method for disease treatment due to simultaneous action on different component of pathogenesis, namely amyloid mass formation in kidney.

FIELD: medicine, pulmonology, pharmacy.

SUBSTANCE: invention relates to compositions comprising beta-2-receptor agonist and steroid used in treatment of inflammatory or obstructive diseases of respiratory ways. Medicinal agent comprises a component (A) representing formoterol or its pharmaceutically acceptable salt or formoterol solvate or indicated salt, and a component (B) representing mometasone furoate designated for treatment of inflammatory or obstructive disease of respiratory ways. The composition provides declining doses or mometasone furoate or formoterol significantly that are necessary for providing the specific therapeutic effect as compared with doses required in treatment in using mometasone furoate or formoterol only. This results to minimization of possible undesirable adverse effects.

EFFECT: improved and valuable medicinal properties of agent and set.

15 cl, 281 ex

FIELD: stomatology, agent for oral cavity health care.

SUBSTANCE: oral antigingivitis composition contains acceptable carrier and combination of non-cation halogenated hydroxybiphenyl ether and extract from Magnolia Cortex, namely Magnolia officinalis cortex, containing hydroxybiphenyl compounds. Method for inhibiting dental plaque bacterium growth includes bacterium contacting with composition, containing acceptable carrier and combination of non-cation halogenated hydroxybiphenyl ether and magnolia extract containing hydroxybiphenyl compounds..

EFFECT: new oral antigingivitis composition.

2 ex, 3 tbl

FIELD: medicine, physiotherapy.

SUBSTANCE: one should prescribe the diet #1, morning exercises, total pearl baths, intake of mineral sulfate-chloride-sodium-magnesium water, manual massage and peloid applications onto area of wide girdle. The impact mentioned should be fulfilled daily at the quantity of 10 procedures. The intake of mineral water mentioned at 6 g/l mineralization should be prescribed thrice daily per 100-150 ml 30 min before meals. Additionally, one should prescribe phytospecies consisting of the following grasses: everlasting, St. John's wort, yarrow, common horsetail and peppermint at the ratio of 3:3:2:2:2, correspondingly per 50 ml thrice daily after meals for 12-14 d. The innovation enables to improve the values of motor-evacuatory function of bile-excretory system, improve biochemical composition of bile, parameters of regional hemodynamics, and, also, improve morphological state of gastric and duodenal mucosa and restore the continuity of mucosal layer.

EFFECT: higher efficiency of therapy.

1 ex, 2 tbl

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with preventing and treating puerperal endometritis in cows. One should introduce the foam into uterine cavity that appears after interacting with warm water containing 10 U oxytocin and a suppository that includes medicinal substances reduced up to amorphous state. Moreover, components in a suppository are in the following ratio, g (weight%): potassium iodide 1.5 (5.4), ephedrine hydrochloride 0.5 (1.8), furacillin 0.5 (1.8), metronidazole (trichopol) 1.5 (5.4), proserine (prostigmin) 0.06 (0.2), analgin 0.5 (1.8), sodium bicarbonate 9.0 (32.7), potato starch 4.0 (14.6), common salt 1.5 (5.4), citric acid 6.9 (25), calcium stearate 0.3 (1.1), 20%-alcoholic solution of MGD-2 emulsifier or MGD-2-similar one 1.3 (4.8). The innovation provides higher efficiency of local impact of medicinal substances upon pathogenic uterine microflora.

EFFECT: higher efficiency.

1 cl, 1 tbl

FIELD: organic chemistry, chemical technology.

SUBSTANCE: invention relates to a new improved method for preparing derivatives of 3,3-diarylpropylamines of the general formula (I) and sterically highly pure stable intermediate substances and their using for preparing pharmaceutical compositions. Method for preparing 3,3-diarylpropylamines of the general formula (I) wherein R means hydrogen atom, linear or branched (C1-C6)-alkyl but preferably methyl or isopropyl; R' and R'' can be similar or different and mean linear or branched (C1-C6)-alkyl but preferably methyl or isopropyl. Method involves condensation of cinnamic acid with compound of the general formula (1) to form compound of the general formula (2a) and the following reaction of the latter with chiral tertiary amine - cinchonidine to yield the corresponding salt of compound of the general formula (2b): and then from this compound the crystalline form of compound of the formula (3): is isolated followed by its either direct reduction with equivalent excess of hydride to yield lactol of the formula (5a) or via intermediate step by formation of corresponding acid chloroanhydride to form ester with alcohols of type R-OH wherein R is given above and the following conversion to compound of the formula (4): and the latter is hydrogenated with diisobutylaluminum-hydride or tri-tert.-butoxyaluminum-hydride to yield lactol of the formula (5) . Prepared lactols of the formula (5a) or (5) after reductive amination with secondary amine form compounds of the formula (I).

EFFECT: improved preparing method.

10 cl, 1 sch, 1 tbl, 13 ex

FIELD: medicine, infectious diseases, psychotherapy.

SUBSTANCE: method involves antiviral therapy, immune correction with thymus hormones and interferon inductors. Since the first day the relapse symptom method involves prescription of antiox+ (1 capsule per a day) and detox+ (1 capsule, 2 times per a day) for 30 days, profluzak (20 mg, 3 times per a day for 5 days) and then in the dose 20 mg, 1 time per a day for 20 days. Derinate is prescribed topically as installation into urethra in the dose 3-5 ml or with tampon into vagina and with simultaneous prescription of microenemas in the dose 10-40 ml for 10 days. Since 10-14 day in exacerbation period in the proliferative stage of an antiherpetic immune response derinate is prescribed by intramuscular injections in the dose 5 ml, 1 time in a day, 10 injections in total number. Then since 6-th day of exacerbation and intake of profluzak psychotherapy seances are carried out. The first seance of rational psychotherapy involves explanation to a patient in available form mechanism of the disease, the necessity of prolonged treatment and motivation for treatment is enhanced by suggestion. The second psychotherapy seance involves neurolinguistic programming wherein a patient colorful and detailed description of desirable function when he imagines achievement of the desire result, and positive emotional and vegetative symptoms are notes and the conditional-reflect association is formed by tactile contact. Under psychotherapist control a patient imagines "part of person" responsible for achievement of the desire result the patient attention is accented for the desire result and arisen physiological responses are fixed by using tactile contact. Also, new behavior methods are proposed to take for a patient that are directed for achievement of the desire result - avoiding sexual contacts during exacerbation of genital herpes in one of partner and during every month hormonal cycles, avoiding stress situations, and in case of each stress situation significant for patient profluzak has to be intake in a single dose 40 mg, using a condom in sexual contact in the exacerbation period. Patient analyzes the proposed new behavior methods that help avoiding relapses, provide good state of health, promotes to recovery process of genitals recovery and selects at least three the most rationally available for him behavior methods. In the case of the positive response that is controlled by physiological symptoms the result is fixed by tactile contact. The third seance involves the suggestive psychotherapy directed for fixing the attained result. The suggestive therapy seance is carried out once per a week for 6 months. Method provides declining the treatment time, to reduce relapse frequency of genital herpes and to recover the emotional state of patient.

EFFECT: improved treatment method.

2 cl, 3 tbl, 1 ex

FIELD: medicine, gynecology.

SUBSTANCE: it is necessary to carry out combined medicinal and physiotherapeutic impact. Mixture of pharmacological preparations consisting of 80 mg gentamycine, 16 U lidase and 4 ml 2%-lidocaine solution should be injected submucosally into lateral vaginal arches followed by dynamic electroneurostimulation in area of uterine adnexa projection for 30 min. Therapy course lasts for 7 d. The innovation enables to shorten therapy terms and prevent the development of complications due to applying physiotherapeutic impact in acute period of purulent-inflammatory process.

EFFECT: higher efficiency of therapy.

FIELD: organic chemistry, antibiotics, pharmacy.

SUBSTANCE: invention relates to 9a-N-[N'-(phenylsulfonyl)carbamoyl]-derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide A that are new semisynthetic macrolide antibiotics relating to class of azalides showing antibacterial effect and describing by the general formula (1):

wherein R1 means hydrogen atom (H), (C1-C4)-alkyl or halogen atom; R means H or cladinosyl radical, and to their pharmaceutically acceptable salts. Also, invention relates to a method for their preparing and a pharmaceutical composition based on thereof.

EFFECT: improved preparing method, valuable medicinal properties of derivatives.

16 cl, 2 tbl, 14 ex

FIELD: organic chemistry, medicine, biochemistry, pharmacy.

SUBSTANCE: invention relates to derivatives of 1,3,2-oxazaphosphacycloalkane of the general formula (I):

wherein Y represents oxygen atom (O) or sulfur atom (S); n = 1, 2, 3 or 4; X represents hydroxamic acid or carboxylic acid; R2 represents hydrogen atom, (C1-C8)-alkyl, (C2-C6)-alkenyl or aryl-(C0-C6)-alkyl, and to their salts, hydrates or solvates. Proposed compounds are inhibitors of matrix metalloproteinases taking part in tissue degradation that suggests the possibility for their using in the human therapy and veterinary.

EFFECT: valuable medicinal properties of compounds.

11 cl, 4 tbl, 242 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to a polymorphic modification of 4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)benzylidene]thiomorpholine-3-one citrate. Invention describes 4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)benzylidene]thiomorpholine-3-one citrate of the formula:

. Also, invention describes a pharmaceutical composition possessing antagonistic activity with respect to serotonine-1D receptor (5-HT1D) comprising the compound by claim 1 and pharmaceutically acceptable carrier, and a method for treatment of hypertension, all forms of depression and other diseases in mammals comprising administration the therapeutically effective dose of compound by claim 1 in needing mammal. Invention provides citrate that is stable in solid state and compatible with excipients in preparing preparations of definite medicines.

EFFECT: improved and valuable pharmaceutical properties of salt.

12 cl, 5 dwg, 8 tbl, 1 ex

FIELD: organic chemistry of heterocyclic compounds, biochemistry.

SUBSTANCE: invention relates to new ortho-substituted and N-substituted indoles of the formula (α): or (β): or their pharmaceutically acceptable salts wherein Z1 represents -CR4 or nitrogen atom (N); R4 means hydrogen atom (H), (C1-C6)-alkyl comprising optionally oxygen atom (O) or nitrogen atom (N) possibly substituted with halogen atom, keto-group, 5-6-membered cycloaliphatic radical possibly comprising 1-2 oxygen atoms (O) or nitrogen atom (N); Z2 represents -CH or -CR wherein R means (C1-C6)-alkyl; R1 means compound of the formula: wherein X1 means -CO or its isostere; m = 0, 1; Y represents alkyl that can be substituted; or two Y form in common (C2-C3)-alkylene; n = 0, 1 or 2; Z3 represents -CH; X2 represents -CH, -CH2 or their isostere; Ar represents one or two phenyl groups bound with X2 wherein phenyl can be substituted; R2 represents hydrogen atom (H), (C1-C6)-alkyl or aryl wherein each aryl comprises, possibly, oxygen atom (O) or nitrogen atom (N) and can be substituted. Proposed compounds are selective inhibitors of p38α kinase.

EFFECT: valuable biochemical properties of compounds.

34 cl, 5 tbl, 23 ex

FIELD: organic chemistry of heterocyclic compounds, biochemistry.

SUBSTANCE: invention relates to new ortho-substituted and N-substituted indoles of the formula (α): or (β): or their pharmaceutically acceptable salts wherein Z1 represents -CR4 or nitrogen atom (N); R4 means hydrogen atom (H), (C1-C6)-alkyl comprising optionally oxygen atom (O) or nitrogen atom (N) possibly substituted with halogen atom, keto-group, 5-6-membered cycloaliphatic radical possibly comprising 1-2 oxygen atoms (O) or nitrogen atom (N); Z2 represents -CH or -CR wherein R means (C1-C6)-alkyl; R1 means compound of the formula: wherein X1 means -CO or its isostere; m = 0, 1; Y represents alkyl that can be substituted; or two Y form in common (C2-C3)-alkylene; n = 0, 1 or 2; Z3 represents -CH; X2 represents -CH, -CH2 or their isostere; Ar represents one or two phenyl groups bound with X2 wherein phenyl can be substituted; R2 represents hydrogen atom (H), (C1-C6)-alkyl or aryl wherein each aryl comprises, possibly, oxygen atom (O) or nitrogen atom (N) and can be substituted. Proposed compounds are selective inhibitors of p38α kinase.

EFFECT: valuable biochemical properties of compounds.

34 cl, 5 tbl, 23 ex

FIELD: organic chemistry of heterocyclic compounds, biochemistry.

SUBSTANCE: invention relates to new ortho-substituted and N-substituted indoles of the formula (α): or (β): or their pharmaceutically acceptable salts wherein Z1 represents -CR4 or nitrogen atom (N); R4 means hydrogen atom (H), (C1-C6)-alkyl comprising optionally oxygen atom (O) or nitrogen atom (N) possibly substituted with halogen atom, keto-group, 5-6-membered cycloaliphatic radical possibly comprising 1-2 oxygen atoms (O) or nitrogen atom (N); Z2 represents -CH or -CR wherein R means (C1-C6)-alkyl; R1 means compound of the formula: wherein X1 means -CO or its isostere; m = 0, 1; Y represents alkyl that can be substituted; or two Y form in common (C2-C3)-alkylene; n = 0, 1 or 2; Z3 represents -CH; X2 represents -CH, -CH2 or their isostere; Ar represents one or two phenyl groups bound with X2 wherein phenyl can be substituted; R2 represents hydrogen atom (H), (C1-C6)-alkyl or aryl wherein each aryl comprises, possibly, oxygen atom (O) or nitrogen atom (N) and can be substituted. Proposed compounds are selective inhibitors of p38α kinase.

EFFECT: valuable biochemical properties of compounds.

34 cl, 5 tbl, 23 ex

FIELD: organic chemistry, medicinal virology, biochemistry, pharmacy.

SUBSTANCE: invention relates to derivatives of pyrazole of the formula (I-A):

wherein R1 means (C1-C12)-alkyl that can be optionally substituted with 1-3 substitutes taken among fluorine, chlorine and bromine atoms, (C3-C8)-cycloalkyl, phenyl, pyridyl or (C1-C4)-alkyl substituted with phenyl; R2' means optionally substituted phenyl wherein phenyl can be substituted with 1-2 substitutes taken among (C1-C4)-alkyl, (C1-C4)-alkoxyl, hydroxyl, fluorine, chlorine and bromine atoms, cyano- and nitro-group; R3 means (C1-C12)-alkyl or (C1-C4)-alkoxy-(C1-C4)-alkyl; A' means (C1-C4)-alkyl optionally substituted with phenyl or optionally substituted with 4-pyridyl wherein phenyl or 4-pyridyl can be substituted with 1-2 substitutes taken among (C1-C4)-alkyl, (C1-C4)-alkoxyl, hydroxyl, fluorine, chlorine and bromine atoms, cyano-group and NRR' wherein R and R' mean independently of one another hydrogen atom or (C1-C4)-alkyl; or A' means group of the formula CH2-U-heterocyclyl wherein U represents O, S or NR'' wherein R'' means hydrogen atom or (C1-C4)-alkyl and wherein heterocyclyl means pyridyl or pyrimidinyl that is optionally substituted with 1-2 substitutes taken among (C1-C4)-alkyl, fluorine, chlorine and bromine atoms, cyano-, nitro-group and NRR' wherein R and R' mean independently of one another hydrogen atom or (C1-C4)-alkyl; or A' means group of the formula CH(OH)-phenyl; or A' means the group CH=CHW wherein W means phenyl; X means S or O, and their pharmaceutically acceptable salts. These compounds are inhibitors of human immunodeficiency virus (HIV) reverse transcriptase and, therefore, can be used in treatment of HIV-mediated diseases. Also, invention relates to a pharmaceutical composition used in treatment of HIV-mediated diseases.

EFFECT: valuable medicinal properties of compounds and composition.

11 cl, 5 tbl, 32 ex

FIELD: organic chemistry, medicinal virology, biochemistry, pharmacy.

SUBSTANCE: invention relates to derivatives of pyrazole of the formula (I-A):

wherein R1 means (C1-C12)-alkyl that can be optionally substituted with 1-3 substitutes taken among fluorine, chlorine and bromine atoms, (C3-C8)-cycloalkyl, phenyl, pyridyl or (C1-C4)-alkyl substituted with phenyl; R2' means optionally substituted phenyl wherein phenyl can be substituted with 1-2 substitutes taken among (C1-C4)-alkyl, (C1-C4)-alkoxyl, hydroxyl, fluorine, chlorine and bromine atoms, cyano- and nitro-group; R3 means (C1-C12)-alkyl or (C1-C4)-alkoxy-(C1-C4)-alkyl; A' means (C1-C4)-alkyl optionally substituted with phenyl or optionally substituted with 4-pyridyl wherein phenyl or 4-pyridyl can be substituted with 1-2 substitutes taken among (C1-C4)-alkyl, (C1-C4)-alkoxyl, hydroxyl, fluorine, chlorine and bromine atoms, cyano-group and NRR' wherein R and R' mean independently of one another hydrogen atom or (C1-C4)-alkyl; or A' means group of the formula CH2-U-heterocyclyl wherein U represents O, S or NR'' wherein R'' means hydrogen atom or (C1-C4)-alkyl and wherein heterocyclyl means pyridyl or pyrimidinyl that is optionally substituted with 1-2 substitutes taken among (C1-C4)-alkyl, fluorine, chlorine and bromine atoms, cyano-, nitro-group and NRR' wherein R and R' mean independently of one another hydrogen atom or (C1-C4)-alkyl; or A' means group of the formula CH(OH)-phenyl; or A' means the group CH=CHW wherein W means phenyl; X means S or O, and their pharmaceutically acceptable salts. These compounds are inhibitors of human immunodeficiency virus (HIV) reverse transcriptase and, therefore, can be used in treatment of HIV-mediated diseases. Also, invention relates to a pharmaceutical composition used in treatment of HIV-mediated diseases.

EFFECT: valuable medicinal properties of compounds and composition.

11 cl, 5 tbl, 32 ex

FIELD: organic chemistry, medicinal virology, biochemistry, pharmacy.

SUBSTANCE: invention relates to derivatives of pyrazole of the formula (I-A):

wherein R1 means (C1-C12)-alkyl that can be optionally substituted with 1-3 substitutes taken among fluorine, chlorine and bromine atoms, (C3-C8)-cycloalkyl, phenyl, pyridyl or (C1-C4)-alkyl substituted with phenyl; R2' means optionally substituted phenyl wherein phenyl can be substituted with 1-2 substitutes taken among (C1-C4)-alkyl, (C1-C4)-alkoxyl, hydroxyl, fluorine, chlorine and bromine atoms, cyano- and nitro-group; R3 means (C1-C12)-alkyl or (C1-C4)-alkoxy-(C1-C4)-alkyl; A' means (C1-C4)-alkyl optionally substituted with phenyl or optionally substituted with 4-pyridyl wherein phenyl or 4-pyridyl can be substituted with 1-2 substitutes taken among (C1-C4)-alkyl, (C1-C4)-alkoxyl, hydroxyl, fluorine, chlorine and bromine atoms, cyano-group and NRR' wherein R and R' mean independently of one another hydrogen atom or (C1-C4)-alkyl; or A' means group of the formula CH2-U-heterocyclyl wherein U represents O, S or NR'' wherein R'' means hydrogen atom or (C1-C4)-alkyl and wherein heterocyclyl means pyridyl or pyrimidinyl that is optionally substituted with 1-2 substitutes taken among (C1-C4)-alkyl, fluorine, chlorine and bromine atoms, cyano-, nitro-group and NRR' wherein R and R' mean independently of one another hydrogen atom or (C1-C4)-alkyl; or A' means group of the formula CH(OH)-phenyl; or A' means the group CH=CHW wherein W means phenyl; X means S or O, and their pharmaceutically acceptable salts. These compounds are inhibitors of human immunodeficiency virus (HIV) reverse transcriptase and, therefore, can be used in treatment of HIV-mediated diseases. Also, invention relates to a pharmaceutical composition used in treatment of HIV-mediated diseases.

EFFECT: valuable medicinal properties of compounds and composition.

11 cl, 5 tbl, 32 ex

FIELD: medicine.

SUBSTANCE: method involves carrying out radical operation in combination with intra-operative radiation therapy at a dose of 15 Gray per removed tumor bed and regional metastasis path. The operation combined with intra-operative radiation therapy is done in 3 weeks after finishing polychemotherapy composed of at least 2 courses to reach positive result of tumor reduction more than 75%. Pause between the courses is 3 weeks long. Following scheme is administered: Hemcytabin 1250 mg/m2 in intravenous drop-by-drop introduction during half-an-hour long infusion at the second and the ninth day, Cisplatin 50 mg/m2 is introduced at the first and the eighth day.

EFFECT: stopped progressive tumor development; prevented metastases formation.

FIELD: food processing industry.

SUBSTANCE: drinking water with increased content of represents industrially obtained light water containing at least 997.13 g/kg (or at least 997.36 g/kg, or at least 997.51 g/kg) based on total water amount, wherein sum amount of 1H2D16O, 1H1D17O, 1H1D18O, and is at most 2.87 g/kg (or at most 2.64 g/kg, or at most 2.49 g/kg) based on total water amount. Drinking water with increased content of is useful in production of dairy, confectionary, bakery, fat-and-oil products, souses, fish and meat products, pasta, chewing gum, soy products, vinegar, vodka, brandy, tincture, balsam, liquor, alcohol cocktail, soft drink, mineralized water, functional products animal feed supplement.

EFFECT: water for optimization of isotopic composition in human body, foodstuffs and beverages of high technological characteristics.

27 cl, 1 dwg, 4 tbl, 26 ex

Up!